Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Rating) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 185,500 shares, an increase of 138.4% from the April 30th total of 77,800 shares. Based on an average trading volume of 1,120,000 shares, the days-to-cover ratio is presently 0.2 days.
Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP bought a new position in shares of Sonoma Pharmaceuticals in the third quarter valued at about $63,000. Squarepoint Ops LLC bought a new position in Sonoma Pharmaceuticals during the third quarter worth about $88,000. Finally, Geode Capital Management LLC increased its position in Sonoma Pharmaceuticals by 22.2% during the third quarter. Geode Capital Management LLC now owns 36,878 shares of the company’s stock worth $205,000 after acquiring an additional 6,697 shares during the period. 5.75% of the stock is currently owned by institutional investors.
Shares of SNOA stock opened at $3.37 on Friday. The stock has a market cap of $10.44 million, a P/E ratio of -1.28 and a beta of 1.01. The company has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $3.89. Sonoma Pharmaceuticals has a one year low of $2.55 and a one year high of $13.36.
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis.
- Get a free copy of the StockNews.com research report on Sonoma Pharmaceuticals (SNOA)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.